<?xml version="1.0" encoding="UTF-8"?>
<ref id="B97-ijms-22-01591">
 <label>97.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Su</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Hong</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Herpai</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Truong</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>W.Y.</given-names>
   </name>
   <name>
    <surname>Wu</surname>
    <given-names>X.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>miR-30 disrupts senescence and promotes cancer by targeting both p16(INK4A) and DNA damage pathways</article-title>
  <source>Oncogene</source>
  <year>2018</year>
  <volume>37</volume>
  <fpage>5618</fpage>
  <lpage>5632</lpage>
  <pub-id pub-id-type="doi">10.1038/s41388-018-0358-1</pub-id>
  <?supplied-pmid 29907771?>
  <pub-id pub-id-type="pmid">29907771</pub-id>
 </element-citation>
</ref>
